Reaction
Renal Neoplasm reporting signals
As of the last recalculation, Renal Neoplasm appears in 2,105 FAERS reports alongside 31 co-occurring drug terms. The strongest observed disproportionality signal is MOMETASONE (PRR 22.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Mometasone | 41 | 22.5 | 22.6 |
| Valsartan Oral | 80 | 15.1 | 15.1 |
| Octreotide Acetate | 43 | 14.1 | 14.2 |
| Valsartan | 105 | 10.3 | 10.4 |
| Midazolam | 26 | 10.3 | 10.3 |
| Haloperidol | 24 | 9.9 | 9.9 |
| Haloperidol Lactate | 24 | 9.7 | 9.7 |
| Midazolam Hydrochloride | 26 | 9.7 | 9.7 |
| Baricitinib | 9 | 9.3 | 9.3 |
| Amlodipine Besylate And Valsartan | 10 | 9.0 | 9.0 |
| Pazopanib Hydrochloride | 24 | 8.9 | 8.9 |
| Isosorbide Dinitrate | 17 | 8.7 | 8.7 |
| Nitroglycerin | 45 | 8.5 | 8.5 |
| Everolimus | 42 | 8.3 | 8.3 |
| Valsartan And Hydrochlorothiazide | 9 | 6.6 | 6.6 |
| Fluticasone Furoate And Vilanterol Trifenatate | 23 | 6.4 | 6.4 |
| Polatuzumab Vedotin | 6 | 6.1 | 6.1 |
| Dexlansoprazole | 22 | 5.3 | 5.3 |
| Lanreotide Acetate | 4 | 5.1 | 5.1 |
| Erlotinib | 4 | 4.1 | 4.1 |
| Niraparib | 9 | 4.0 | 4.0 |
| Ibrutinib | 31 | 3.8 | 3.8 |
| Olaparib | 8 | 3.8 | 3.8 |
| Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose | 3 | 3.6 | 3.6 |
| Ustekinumab | 35 | 3.4 | 3.4 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate | 3 | 3.3 | 3.3 |
| Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate | 5 | 2.7 | 2.7 |
| Vigabatrin | 4 | 2.7 | 2.7 |
| Orlistat | 7 | 2.7 | 2.7 |
| Emtricitabine And Tenofovir Alafenamide | 3 | 2.6 | 2.6 |
| Ranitidine Hydrochloride | 11 | 2.0 | 2.0 |